Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

40.04
+0.37000.93%
Pre-market: 40.480.4400+1.10%04:01 EDT
Volume:786.77K
Turnover:31.56M
Market Cap:3.85B
PE:-20.47
High:40.46
Open:39.73
Low:39.12
Close:39.67
52wk High:40.58
52wk Low:23.23
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.88
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.22
PE(LYR):-31.16

Loading ...

Ideaya Biosciences announces $300M common stock offering

TIPRANKS
·
Jun 09

IDEAYA Biosciences plans public offering of up to $300 million in common stock, pre-funded warrants

Reuters
·
Jun 09

IDEAYA Biosciences - to Grant Underwriters 30-Day Option to Purchase up to $45 Mln of Common Stock

THOMSON REUTERS
·
Jun 09

IDEAYA Biosciences - Announces Proposed Public Offering of up to $300 Mln in Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Jun 09

IDEAYA Biosciences files Form 3 for Chief Development Officer Theodora Ross

Reuters
·
Jun 06

Analysts Have Conflicting Sentiments on These Healthcare Companies: IDEAYA Biosciences (IDYA) and Diaceutics (OtherDIUXF)

TIPRANKS
·
Jun 04

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Jun 03

Ideaya Biosciences Teams With Roche to Test Combination Therapy in Pancreatic Cancer

MT Newswires Live
·
Jun 03

Ideaya Biosciences announces IDE892 collaboration with Roche

TIPRANKS
·
Jun 03

IDEAYA Biosciences, Roche collaborate on IDE892-RG6505 combo study in MTAP-deleted RAS-mutant pancreatic cancer

Reuters
·
Jun 03

IDEAYA Biosciences Announces Clinical Collaboration With Roche in Mtap-Deleted Ras-Mutant Pancreatic Cancer

THOMSON REUTERS
·
Jun 03

IDEAYA Biosciences - Co and Roche Retain All Commercial Rights to Their Respective Compounds

THOMSON REUTERS
·
Jun 03

IDEAYA Biosciences - to Sponsor Clinical Trial With Joint Governance With Roche

THOMSON REUTERS
·
Jun 03

IDEAYA Biosciences - to Initiate Phase 1 Combination Cohorts in Pdac and Nsclc

THOMSON REUTERS
·
Jun 03

IDEAYA Biosciences Price Target Maintained With a $58.00/Share by Wedbush

Dow Jones
·
Jun 02

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)

TIPRANKS
·
Jun 02

IDEAYA darovasertib-crizotinib combo cuts progression risk in Phase 2/3 OptimUM-02 metastatic uveal melanoma trial

Reuters
·
Jun 01

IDEAYA Biosciences and Servier Provide Complete Data From Phase 2/3 Registrational Optimum-02 Trial of the Darovasertib Combination in First Line Hla*a2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at Asco

THOMSON REUTERS
·
Jun 01

IDEAYA Biosciences grants 221,000 inducement stock options at USD 29.34 per share

Reuters
·
May 29

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 29